Last $14.27 USD
Change Today -0.15 / -1.04%
Volume 357.0K
VNDA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for vanda pharmaceuticals inc (VNDA)

Year over year, Vanda Pharmaceuticals, Inc. has been able to grow revenues from $32.7M USD to $33.9M USD. This was a driver that led to an improvement in the bottom line from a loss of $27.7M USD to a smaller loss of $20.3M USD.
Currency in
Millions of US Dollars
As of:Dec 31
2010
Reclassified
Dec 31
2011
Reclassified
Dec 31
2012
Reclassified
Dec 31
2013
4 Year
Trend
Revenues35.731.332.733.9
TOTAL REVENUES35.731.332.733.9
Cost of Goods Sold5.9--0.1--
GROSS PROFIT29.831.332.633.9
Selling General & Admin Expenses, Total10.812.414.625.2
R&D Expenses8.828.144.827.5
Depreciation & Amortization, Total1.51.51.51.5
OTHER OPERATING EXPENSES, TOTAL21.042.060.854.3
OPERATING INCOME8.8-10.7-28.2-20.4
Other Non-Operating Income (Expenses)0.40.50.60.1
EBT, EXCLUDING UNUSUAL ITEMS9.3-10.2-27.7-20.3
EBT, INCLUDING UNUSUAL ITEMS9.3-10.2-27.7-20.3
Income Tax Expense2.1-0.4----
Earnings from Continuing Operations7.2-9.8-27.7-20.3
NET INCOME7.2-9.8-27.7-20.3
NET INCOME TO COMMON INCLUDING EXTRA ITEMS7.2-9.8-27.7-20.3
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS7.2-9.8-27.7-20.3
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $14.27 USD -0.15

VNDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,354 GBp +8.50
Eli Lilly & Co $62.84 USD +0.31
Sanofi €75.81 EUR +0.11
Sumitomo Dainippon Pharma Co Ltd ¥1,146 JPY +6.00
Transcept Pharmaceuticals Inc $2.16 USD 0.00
View Industry Companies
 

Industry Analysis

VNDA

Industry Average

Valuation VNDA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.7x
Price/Book 23.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.